Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
26.74 USD | -2.12% | -14.62% | 0.00% |
May. 14 | Goldman Sachs Upgrades CG Oncology to Buy From Neutral With $50 Price Target | MT |
May. 09 | CG Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | 1.66M | Sales 2025 * | 8.78M | Capitalization | 1.82B |
---|---|---|---|---|---|
Net income 2024 * | -88M | Net income 2025 * | -112M | EV / Sales 2024 * | 1,025 x |
Net cash position 2024 * | 117M | Net cash position 2025 * | 134M | EV / Sales 2025 * | 192 x |
P/E ratio 2024 * |
-16
x | P/E ratio 2025 * |
-13.5
x | Employees | 61 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.95% |
1 day | +5.69% | ||
1 week | -19.56% | ||
Current month | -32.05% | ||
1 month | -31.30% | ||
3 months | -37.10% |
Managers | Title | Age | Since |
---|---|---|---|
Arthur Kuan
CEO | Chief Executive Officer | 34 | 17-11-29 |
Ambaw Bellete
PSD | President | 54 | 23-06-30 |
Vijay Kasturi
CTO | Chief Tech/Sci/R&D Officer | 57 | 23-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Susan Graf
BRD | Director/Board Member | 52 | Nov. 19 |
Leonard Post
BRD | Director/Board Member | 72 | 18-10-21 |
Victor Tong
BRD | Director/Board Member | 41 | 23-06-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-15 | 27.29 | -0.11% | 62 211 |
24-05-14 | 27.32 | +5.73% | 1,448,007 |
24-05-13 | 25.84 | -9.33% | 948,639 |
24-05-10 | 28.5 | -5.06% | 762,412 |
24-05-09 | 30.02 | -7.43% | 694,145 |
Delayed Quote Nasdaq, May 14, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 1.82B | |
+29.03% | 49.18B | |
-0.10% | 42.11B | |
+48.77% | 40.37B | |
-5.26% | 28.85B | |
+11.48% | 26.09B | |
-22.74% | 18.71B | |
+9.06% | 13.26B | |
+30.01% | 12.32B | |
-1.51% | 11.99B |
- Stock Market
- Equities
- CGON Stock